Kane Biotech Inc. (CVE:KNE – Get Free Report) fell 14.3% during mid-day trading on Friday. The stock traded as low as C$0.03 and last traded at C$0.03. Approximately 111,975 shares changed hands during mid-day trading, a decline of 25% from the average session volume of 149,634 shares. The stock had previously closed at C$0.04.
Kane Biotech Stock Performance
The company’s fifty day simple moving average is C$0.03 and its 200 day simple moving average is C$0.03. The company has a current ratio of 0.61, a quick ratio of 0.39 and a debt-to-equity ratio of -197.52. The stock has a market capitalization of C$6.15 million, a P/E ratio of -1.50 and a beta of 0.60.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
See Also
- Five stocks we like better than Kane Biotech
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
